文献速递眼底病与葡萄膜炎

FILLY试验中补体抑制剂Pegcetacoplan治疗地图样萎缩后新发渗出特征分析

Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
PubMed 文献 · Ophthalmology · 2021-03-10

该研究对FILLY 2期试验中246例地图样萎缩患者进行事后分析,评估玻璃体腔注射Pegcetacoplan后新发渗出性年龄相关性黄斑变性(eAMD)的临床特征。18个月内26只研究眼出现渗出,平均诊断时间256天,基线对侧眼eAMD病史和研究眼双层征(DLS)与新发eAMD相关,渗出对视力无明显影响且均对抗VEGF治疗有反应。

要点

  • 基线对侧眼eAMD病史和研究眼DLS是新发渗出的相关因素。
  • 新发eAMD平均诊断时间为256天,范围31-555天。
  • 渗出性病变对视力无明显影响,所有患者对抗VEGF治疗有反应。

核心结论

  • 玻璃体腔注射Pegcetacoplan与剂量依赖性的新发eAMD发生率增加相关,但发生时间无聚集性。
  • 新发eAMD似乎与基线对侧眼eAMD病史及研究眼DLS(提示非渗出性MNV)相关。
  • Pegcetacoplan的安全性特征可接受,无需调整入组标准即可进入3期研究。

研究设计与样本

  • FILLY 2期研究的事后分析,纳入246例继发于AMD的地图样萎缩患者。
  • 干预为15 mg玻璃体腔注射Pegcetacoplan或假注射,每月或隔月一次,持续12个月,随后6个月停药观察。

主要发现

  • 18个月内共26只研究眼报告渗出,平均诊断时间256天(范围31-555天)。
  • 基线有对侧眼eAMD病史的患者中eAMD发生率更高(P=0.016),研究眼有DLS者亦然(P=0.0001)。
  • 发生eAMD的26眼中18眼(69%)有对侧眼eAMD病史,19眼(73.1%)有基线DLS;未发生eAMD的眼中分别为76/217眼(35%,P=0.0007)和70/215眼(32.5%,P<0.0001)。
  • 诊断eAMD时21例有OCT影像的患者均显示视网膜下液、视网膜内囊样积液或两者兼有。
  • 17例诊断时行FA的患者中10例显示可检测的MNV,均为隐匿性病变。

关键数值与推荐

  • 新发eAMD诊断平均时间256天(范围31-555天)。
  • 发生eAMD组中对侧眼eAMD病史比例69%(18/26),未发生组35%(76/217),P=0.0007。
  • 发生eAMD组中基线DLS比例73.1%(19/26),未发生组32.5%(70/215),P<0.0001。
  • FA可检测MNV的比例为10/17,均为隐匿性。

临床怎么用

  • 对于计划接受补体抑制剂治疗的地图样萎缩患者,应关注对侧眼eAMD病史和基线OCT上的DLS。
  • 治疗期间新发渗出可通过OCT发现视网膜下液或视网膜内囊样积液,必要时行FA确认MNV。
  • 新发eAMD对视力影响不明显,且对抗VEGF治疗有反应,提示可管理。

局限性

  • 为2期试验的事后分析,样本量有限(n=246),新发eAMD事件数较少(26眼)。
  • 原文未报告渗出与剂量关系的具体数值及统计检验细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate clinical characteristics of eyes in which investigator-determined new-onset exudative age-related macular degeneration (eAMD) developed during the FILLY trial. DESIGN: Post hoc analysis of the phase 2 study of intravitreal pegcetacoplan in geographic atrophy (GA). SUBJECTS: Patients with GA secondary to age-related macular degeneration (AMD), n = 246. INTERVENTION: Either 15 mg intravitreal pegcetacoplan or sham given monthly or every other month for 12 months followed by a 6-month off-treatment period. MAIN OUTCOME MEASURES: Time of new eAMD onset in the study eye, history of eAMD in the fellow eye, presence of double-layer sign (DLS) on structural OCT in the study eye, changes in retinal anatomic features by structural OCT and fluorescein angiography (FA), and changes in visual acuity. RESULTS: Exudation was reported in 26 study eyes across treatment groups over 18 months. Mean time to eAMD diagnosis was 256 days (range, 31-555 days). Overall, a higher proportion of patients with a baseline history of eAMD in the fellow eye (P = 0.016) and a DLS in the study eye (P = 0.0001) demonstrated eAMD. Among study eyes in which eAMD developed, 18 of 26 (69%) had history of fellow-eye eAMD and 19 of 26 (73.1%) had DLS at baseline, compared with 76 of 217 study eyes (35%; P = 0.0007) and 70 of 215 study eyes (32.5%; P < 0.0001), respectively, in which eAMD did not develop. All 21 patients with structural OCT imaging at the time of eAMD diagnosis demonstrated subretinal fluid, intraretinal cysts, or both consistent with exudation. Among 17 patients who underwent FA at eAMD diagnosis, 10 showed detectable macular neovascularization (MNV), all occult lesions. Development of eAMD did not have an appreciable impact on visual acuity, and all patients responded to anti-vascular endothelial growth factor (VEGF) therapy. CONCLUSIONS: Intravitreal pegcetacoplan slowed the rate of GA growth and was associated with an unexpected dose-dependent increased incidence of eAMD with no temporal clustering of onset. Exudative AMD seemed to be associated with baseline eAMD in the contralateral eye and a DLS, suggestive of nonexudative MNV, in the study eye. The safety profile of pegcetacoplan was acceptable to proceed to phase 3 studies without adjustments to enrollment criteria.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Wykoff CC, Rosenfeld PJ, Waheed NK, et al. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021. PMID: 33711380. doi:10.1016/j.ophtha.2021.02.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。